Biotech entity
The clearest coverage concentration is pharma: 6 of 7 stories, with the rest divided among 1 other category. Of the tracked stories, 6 of 7 also mention Weiss Ratings, the most common co-covered peer. Negative sentiment reaches 0% here, compared with 19% across the 234-story beat baseline for the same window.
Last mentioned: 3d ago
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
The clearest coverage concentration is pharma: 6 of 7 stories, with the rest divided among 1 other category. Of the tracked stories, 6 of 7 also mention Weiss Ratings, the most common co-covered peer. Negative sentiment reaches 0% here, compared with 19% across the 234-story beat baseline for the same window. At 5, the average consequence score sits below the same-window beat average of 6.1. Source depth averages 2 original sources per story, versus 3.7 across the same-window beat baseline. The 41-day window averages about 1.2 stories each week. The busiest single day carried 2. We currently track 7 Biotech stories that mention MarketBeat, published between July 10, 2026 and August 19, 2026.
Computed from the 7 stories linked to this entity, with beat comparisons drawn from all 234 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering MarketBeat. Shared-story counts are live from our verified record — not editorial picks.
Shares drop 1.8%
APYX traded as low as $4.34 and last at $4.38 on volume of 43,859 shares, 60% below average.
Weiss Ratings reiterates sell
Weiss Ratings reissued a sell (d-) rating on Apyx Medical shares.
Q1 earnings beat
Apyx Medical reported Q1 EPS of -$0.05 vs -$0.11 expected and revenue of $12.49M vs $10.53M expected.
Wall Street Zen downgrades APYX
Wall Street Zen lowered Apyx Medical from a buy rating to a hold rating.
Moderna appears on both MarketBeat's value and large-cap high-volume screens on August 19, underscoring unusual liquidity and renewed biotech interest despite a post-COVID valuation reset. The mRNA pipeline spans respiratory, latent, and public health vaccines, setting up multiple clinical catalysts.
Source: watchlistnews.com · tickerreport.com
For biotech and pharma investors, Apyx Medical's Q1 loss of $0.05 per share beat consensus by $0.06, but the stock fell 1.8% to $4.38 on low volume. Mixed analyst ratings and a $6.50 consensus target raise questions about whether the small-cap device maker can convert clinical and operational beats into stock appreciation. Institutional repositioning signals ongoing evaluation of the company's commercial ramp.
Source: dailypolitical.com · tickerreport.com
Shares of Entera Bio slipped 0.6% to $1.54 on 78% below-average volume, but analysts remain deeply split: HC Wainwright reiterates buy while Weiss Ratings maintains a sell. The $9.00 consensus target implies roughly 484% upside for the $75.91M microcap biotech.
Source: dailypolitical.com · tickerreport.com
Palvella Therapeutics stock sank 12.4% Monday with no news, highlighting biotech liquidity risk. Analyst consensus target of $199.53 implies 45% upside, but earnings miss and two sell ratings complicate the picture for biotech investors.
Source: dailypolitical.com · tickerreport.com
Short interest in CDT Equity, the ticker for clinical-stage biotech Conduit Pharmaceuticals, jumped 70.8% after the stock plunged from a $610 high to just $0.71. With a market cap of $3.45 million and no approved products, the spike in bearish bets underscores the deep skepticism around its early-stage pipeline for autoimmune diseases and infertility.
Source: themarketsdaily.com · tickerreport.com
Wall Street Zen upgraded biotech Agenus to buy despite a massive Q1 earnings miss, as the stock surged 189% from its 52-week low. Mixed analyst views and a $30 HC Wainwright target highlight the speculative upside in immuno-oncology.
Source: tickerreport.com · dailypolitical.com
Biotech and life sciences investors face a paradox: ResMed’s stalwart medical device business is underpinned by low debt and high margins, yet analyst targets range from $225 to $321 as GLP-1 therapies threaten its patient base.
Source: Ticker Report · Watch List News
MarketBeat is linked from 7 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
